-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Initiates Coverage On Chemed with Buy Rating, Announces Price Target of $650

Benzinga·09/25/2026 16:00:19
语音播报
UBS analyst A.J. Rice initiates coverage on Chemed (NYSE:CHE) with a Buy rating and announces Price Target of $650.